Resumes
Resumes
Yan Poon Phones & Addresses
-
1106 Belleau St, San Leandro, CA 94579
Publications
Us Patents
Methods Of Inhibiting Pathological Angiogenesis
View pageUS Patent:
20200253991, Aug 13, 2020
Filed:
Feb 14, 2020
Appl. No.:
16/791960
Inventors:
- Brisbane CA, US
Jill Hopkins - Brisbane CA, US
Harry Sweigard - Brisbane CA, US
Yan Poon - Brisbane CA, US
Jamie Dananberg - Brisbane CA, US
Daniel Marquess - Brisbane CA, US
Nathaniel David - Brisbane CA, US
Jill Hopkins - Brisbane CA, US
Harry Sweigard - Brisbane CA, US
Yan Poon - Brisbane CA, US
Jamie Dananberg - Brisbane CA, US
Daniel Marquess - Brisbane CA, US
Nathaniel David - Brisbane CA, US
International Classification:
A61K 31/635
A61P 27/02
A61P 27/02
Abstract:
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
Technology To Inhibit Progression Of Neovascularization And Vaso-Obliteration
View pageUS Patent:
20190151337, May 23, 2019
Filed:
Oct 15, 2018
Appl. No.:
16/160840
Inventors:
- Brisbane CA, US
- Novato CA, US
Harry Sweigard - Brisbane CA, US
Yan Poon - Brisbane CA, US
Jamie Dananberg - Brisbane CA, US
Daniel Marquess - Brisbane CA, US
Nathaniel David - Brisbane CA, US
- Novato CA, US
Harry Sweigard - Brisbane CA, US
Yan Poon - Brisbane CA, US
Jamie Dananberg - Brisbane CA, US
Daniel Marquess - Brisbane CA, US
Nathaniel David - Brisbane CA, US
International Classification:
A61K 31/635
A61K 9/00
A61P 27/02
A61K 9/00
A61P 27/02
Abstract:
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.